Exicure, Inc. (NASDAQ:XCUR) Shares Shorted: Short Interest Down 46.9% in September

Exicure, Inc. (NASDAQ:XCUR) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 37,561 shares, a decrease of 46.9% from the September 15th total of 70,672 shares. Based on an average daily trading volume, of 18,763 shares, the short-interest ratio is currently 2.0 days. Approximately 1.2% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Exicure in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Exicure Price Performance

XCUR stock opened at $1.21 on Thursday. The firm has a fifty day moving average price of $1.26 and a 200 day moving average price of $2.27. Exicure has a fifty-two week low of $0.94 and a fifty-two week high of $9.48.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($18.60) by $18.42.

Exicure Company Profile

Exicure, Inc is a biotechnology company that historically focused on developing nucleic acid-based medicines. Its research was built around Spherical Nucleic Acid (SNA) technology, a platform designed to package and deliver short strands of genetic material into cells to influence disease-related biological pathways.

The company’s development programs included investigational treatments for oncology, inflammatory diseases and genetic disorders. Its most prominent candidates included cavrotolimod, an immunotherapy designed to activate the toll-like receptor 9 pathway, and earlier dermatology-focused programs intended to address conditions such as psoriasis and related inflammatory diseases.